TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
JAMCO Pharma Consulting AB
Closing information (x1000 EUR)
| Closing information | 2025/09 | 2024/09 | 2023/09 |
| Turnover |
466
|
517
|
575 |
| Financial expenses |
2
|
0
|
0 |
| Earnings before taxes |
309
|
366
|
399 |
| EBITDA |
309
|
327
|
364 |
| Total assets |
2,394
|
2,246
|
1,935 |
| Current assets |
274
|
249
|
754 |
| Current liabilities |
111
|
222
|
249 |
| Equity capital |
2,215
|
1,975
|
1,657 |
| - share capital |
5
|
4
|
4 |
| Employees (average) |
2
|
2
|
2 |
Financial ratios
| Fiscal year | 2025/09 | 2024/09 | 2023/09 |
| Solvency |
92.5%
|
87.9%
|
85.6% |
| Turnover per employee |
233
|
258
|
288 |
| Profit as a percentage of turnover |
66.3%
|
70.8%
|
69.4% |
| Return on assets (ROA) |
13.0%
|
16.3%
|
20.6% |
| Current ratio |
246.8%
|
112.2%
|
302.8% |
| Return on equity (ROE) |
14.0%
|
18.5%
|
24.1% |
| Change turnover |
-62
|
-68
|
44 |
| Change turnover % |
-12%
|
-12%
|
8% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2025/09 | 2024/09 | 2023/09 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.